Our Mission
The BDFA’s mission is to enable everyone who is affected by Batten disease to live life to the full and secure the care and support they need until we find a cure.
The BDFA offers informed guidance and supports families and professionals who work with them as well as actively increasing awareness of the disease and funding future research to identify potential therapies and ultimately a range of cures.
The BDFA works across the rare disease sector to influence change in policy and processes as a collective voice.
Latest News
Big Give Christmas Challenge 2024 total announced!
A grand total of £21,660 including Gift Aid has been raised through our Big Give Christmas Challenge 2024!We would like to take a moment to convey our sincere thanks to…
Big Give Christmas Challenge 2024 – Now live!
Our Big Give Christmas Challenge campaign page is now open and doubling donations! We are aiming to raise £15,000 to go towards our Family Support Service and New Bereavement Project…
BDFA Christmas cards now on sale!
The BDFA Christmas card packs are now available for purchase in our online shop! This years card design features some of our amazing Batten families. All proceeds go directly towards…
BDFA response to extension of Brineura Managed Access Agreement for the treatment of CLN2
BDFA response to extension of Brineura Managed Access Agreement for the treatment of CLN2 Managed Access Agreement extension for six months The National Institute for Health and Care Excellence (NICE)…
Cambridge Institute of Music Therapy running research project for children with Batten disease
We are thrilled to announce that the Cambridge Institute of Music Therapy will be running a research project for children with Batten disease this year. Funded by the Worshipful Company…
Latest News
News on the BDFA Charity Incorporation
The Trustees and team are pleased to advise that on 1 September 2024 the Batten Disease Family Association transitioned to a Charitable Incorporated Organisation (CIO) formed under the Charities Act…
Tern Therapeutics enters into a global licensing agreement with REGENXBIO Inc. for RGX-381 and RGX-181
The BDFA is delighted to share that Tern Therapeutics, a biotechnology company based in the USA have entered into a global licensing agreement with REGENXBIO Inc. for RGX-381 and RGX-181.…
The Second NICE Committee Meeting to assess the use of Brineura on the NHS- 5th September
20/08/2024Dear Families,We wanted to provide you with an update on the second NICE committee meeting to assess the use of Brineura on the NHS.Following a brief pause in the process…
Global Update – Clinical Trial in CLN5 disease update from Neurogene Inc.
We are pleased to advise that Neurogene Inc. have announced that enrollment is now complete for its Phase 1/2 investigational trial of NGN-101 Gene Therapy for the treatment of CLN5…
Batten Disease Global Research Initiative Grants- Now Open for Expressions of Interest until AUGUST 30th
Together, the BDFA, with our Global Research Initiative (GRI) partners, is delighted to announce the inaugural GRI Grant Round is now inviting Expressions of Interest. We seek to support the most…
Visit the online shop to help support the work of the BDFA
